Scarica l'app Stockscreener
7.40
0.00%
0.00
Dopo l'orario di chiusura:
7.37
-0.03
-0.41%
Kezar Life Sciences Inc Borsa (KZR) Ultime notizie
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
Kezar Life Sciences Announces Lease Termination and Executive Separation Agreements in April 2026 - Minichart
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
KZR PE Ratio & Valuation, Is KZR Overvalued - Intellectia AI
Kezar Life Sciences announces lease termination and executive departures following merger agreement - ca.investing.com
Kezar Life Sciences Announces Major Executive Leadership Changes - tipranks.com
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - tipranks.com
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - Stock Titan
Kezar Life Sciences' Christopher J. Kirk, Marc L. Belsky and Mark Schiller to Depart under Separation Agreements - TradingView
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - Stock Titan
KZR Technical Analysis & Stock Price Forecast - Intellectia AI
Major Kezar (KZR) shareholder signs merger support pact and drops bid - Stock Titan
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Trend Recap: What is Kezar Life Sciences Incs market position2026 Chart Watch & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders? - Sahm
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Cash Deal - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
Jefferies maintains Kezar Life Sciences stock rating on acquisition By Investing.com - Investing.com India
Jefferies maintains Kezar Life Sciences stock rating on acquisition - Investing.com
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - MarketScreener
Shareholder Alert: The Ademi Firm investigates whether Kezar Lif - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - PR Newswire
US Market Wrap: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Aurinia to acquire Kezar Life Sciences for $6.955 per share By Investing.com - Investing.com South Africa
The Ademi Firm Investigates Whether Kezar Life Sciences, Inc. Is Obtaining a Fair Price for Public Shareholders - Moomoo
Aurinia Pharmaceuticals Acquires Kezar Life Sciences - Contract Pharma
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal - tipranks.com
Kezar Life Sciences stock jumps on Aurinia acquisition deal By Investing.com - Investing.com Australia
Kezar Life Sciences stock jumps on Aurinia acquisition deal - Investing.com
Kezar Life Sciences to Be Acquired by Aurinia in $6.955-Per-Share Cash Tender Offer Plus CVR - TradingView
Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR - Stock Titan
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
Aurinia to acquire Kezar Life Sciences for $6.955 per share - Investing.com
What is the next catalyst for Kezar Life Sciences Inc2026 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Kezar Life Sciences 2025 Annual Report: Strategic Alternatives, Clinical Pipeline, and Key Risks - Minichart
KZR: Net loss narrowed to $56M in 2025 as restructuring and strategic review efforts continued - TradingView
[10-K] Kezar Life Sciences, Inc. Files Annual Report - Stock Titan
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Kezar Life Sciences (KZR) to Release Earnings on Tuesday - Defense World
Highs Report: Can Kezar Life Sciences Inc maintain its current growth rate2026 Key Highlights & Weekly Breakout Watchlists - baoquankhu1.vn
If You Invested $1,000 in Kezar Life Sciences (KZR) - Stock Titan
Bull Bear: Is EEIQ still a buy after recent gains2026 Big Picture & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Analyst Downgrade: Is Kezar Life Sciences Inc undervalued by DCF analysis2026 Retail Activity & Daily Market Momentum Tracking - baoquankhu1.vn
Kezar Life Sciences Inc expected to post a loss of $1.23 a shareEarnings Preview - TradingView
Kezar Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | 2KZ0 | US49372L2097 - marketscreener.com
Enodia jumps ahead in Sec61 targeting, adds Kezar’s program - BioWorld MedTech
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):